Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Antimicrobial blue light and photodynamic therapy inhibit clinically relevant 8-lactamases with extended-spectrum (ESBL) and carbapenemase activity

Full text
Author(s):
dos Anjos, Carolina [1] ; Sellera, Fabio P. [1] ; Ribeiro, Martha S. [2] ; Baptista, Mauricio S. [3] ; Pogliani, Fabio C. [1] ; Lincopan, Nilton [4, 5] ; Sabino, Caetano P. [6, 5]
Total Authors: 7
Affiliation:
[1] Univ Sao Paulo, Sch Vet Med & Anim Sci, Dept Internal Med, Sao Paulo - Brazil
[2] Natl Commiss Nucl Energy, Ctr Lasers & Applicat, Nucl & Energy Res Inst, Sao Paulo, SP - Brazil
[3] Univ Sao Paulo, Dept Biochem, Inst Chem, Sao Paulo, SP - Brazil
[4] Univ Sao Paulo, Dept Microbiol, Inst Ciencias Biomed, Sao Paulo - Brazil
[5] Univ Sao Paulo, Dept Clin Anal, Fac Pharmaceut Sci, Sao Paulo - Brazil
[6] BioLambda Sci & Commercial LTD, Sao Paulo, SP - Brazil
Total Affiliations: 6
Document type: Journal article
Source: Photodiagnosis and Photodynamic Therapy; v. 32, DEC 2020.
Web of Science Citations: 0
Abstract

Introduction: The production of beta-lactamases by Gram-negative bacteria is among the most important factors of resistance to antibiotics, which has contributed to therapeutic failures that currently threaten human and veterinary medicine worldwide. Antimicrobial photodynamic therapy and antimicrobial blue light have a broadspectrum antibacterial activity against multidrug-resistant and hypervirulent pathogens. Objective: To investigate the ability of antimicrobial blue light to inhibit the hydrolytic activity of clinically relevant beta-lactamase enzymes (i.e., KPC, IMP, OXA, CTX-M, and SHV), with further comparison of the inhibitory effects of antimicrobial blue light with methylene blue-mediated antimicrobial photodynamic therapy. Methods: Blue LED light (A = 410 +/- 10 nm) alone or red LED light (A = 660 +/- 10 nm) in combination with methylene blue were used to inactivate, in vitro, suspensions of Klebsiella pneumoniae strains producing clinically important beta-lactamase enzymes assigned to the A, B and D Ambler molecular classes. Furthermore, beta-lactamase activity inhibition mediated by antimicrobial blue light and methylene blue-mediated antimicrobial photodynamic therapy was measured by using the chromogenic beta-lactam substrate nitrocefin. Results: beta-lactamase activities were effectively inactivated by both visible light-based approaches. In this regard, antimicrobial blue light and methylene blue-antimicrobial photodynamic therapy led to a significant reduction in the hydrolysis of nitrocefin (81-98 %). Conclusion: Sublethal doses of antimicrobial blue light and methylene blue-mediated antimicrobial photodynamic therapy are equally effective to inhibit clinically significant beta-lactamases, including extended-spectrum beta-lactamases and carbapenemases. (AU)

FAPESP's process: 16/25095-2 - BACTERIAL PHOTOINACTIVATION OF MASTITIS PATHOGENS BY BLUE LIGHT: MECHANISMS OF ACTION AND CELL SECURITY - PRE-CLINICAL STUDY
Grantee:Carolina dos Anjos
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 19/10851-4 - SYNERGISTIC ACTIVITY OF BLUE LIGHT IN COMBINATION WITH CHEMOTHERAPEUTIC ANTIMICROBIAL AGAINST DRUG-RESISTANT PATHOGENS
Grantee:Carolina dos Anjos
Support Opportunities: Scholarships abroad - Research Internship - Doctorate
FAPESP's process: 17/22406-0 - Development of a smart clinical equipment for phototherapies with automatic dosimetry calibration and on demand payment
Grantee:Caetano Padial Sabino
Support Opportunities: Research Grants - Innovative Research in Small Business - PIPE